{"nctId":"NCT00297830","briefTitle":"Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation","startDateStruct":{"date":"2005-11"},"conditions":["Heart Transplantation","Liver Transplantation","Bone Resorption"],"count":111,"armGroups":[{"label":"Active Zoledronic Acid & Placebo Alendronate","type":"EXPERIMENTAL","interventionNames":["Drug: Zoledronic acid","Other: Placebo Alendronate"]},{"label":"Placebo Zoledronic Acid & Active Alendronate","type":"EXPERIMENTAL","interventionNames":["Drug: Alendronate","Other: Placebo Zoledronic Acid"]}],"interventions":[{"name":"Zoledronic acid","otherNames":["Zometa"]},{"name":"Alendronate","otherNames":["Fosamax"]},{"name":"Placebo Zoledronic Acid","otherNames":[]},{"name":"Placebo Alendronate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A man or woman, aged 20 to 70, of any race who has had a heart or liver transplant\n\nExclusion Criteria:\n\n* hyperparathyroidism\n* Paget's disease\n* hyperthyroidism\n* cancer\n* severe kidney disease,\n* intestinal disease\n* active peptic ulcer disease\n* current or past treatment for osteoporosis\n* pregnancy or lactation\n* severe oral/dental disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Change From Baseline in Total Hip Bone Mineral Density (BMD) at 12 Months","description":"BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.39","spread":null},{"groupId":"OG001","value":"-0.21","spread":null},{"groupId":"OG002","value":"-2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months","description":"BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":null},{"groupId":"OG001","value":"-0.45","spread":null},{"groupId":"OG002","value":"-2.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Femoral Neck Bone Mineral Density (BMD) at 12 Months","description":"BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":null},{"groupId":"OG001","value":"-0.57","spread":null},{"groupId":"OG002","value":"-3.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum N-telopeplide Percent Change","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":41},"commonTop":["Infection","Hypocalcemia","Serum Calcium > 2.0 mg/dL","Rejection","Flu-like symptoms after zoledronate or matching placebo"]}}}